Pharmaceuticals, Biotechnology and Life Sciences
TG4050: first patients treated in two clinical trials of the novel individualized immunotherapy based on the myvac® technology – First data expected in 4Q 2021
TG4001: expanded randomized Phase II trial to start in HPV-positive anogenital cancers…
– Enrollment of the first patient is expected in Q2 2021
– Trial will focus on patients without liver metastases, based on encouraging data in Phase Ib/II study
– Trial targets indications where clinical outcomes can be improved versus standard therap…
TG4050: first patients treated in two clinical trials of the novel individualized immunotherapy based on the myvac® technology – First data expected in 4Q 2021
TG4001: expanded randomized Phase II trial to start in HPV-positive anogenital cancers…
TG4050: first patients treated in two clinical trials of the novel individualized immunotherapy based on the myvac® technology – First data expected in 4Q 2021
TG4001: expanded randomized Phase II trial to start in HPV-positive anogenital cancers…
TG4050: first patients treated in two clinical trials of the novel individualized immunotherapy based on the myvac® technology – First data expected in 4Q 2021
TG4001: expanded randomized Phase II trial to start in HPV-positive anogenital cancers…
TG4050: first patients treated in two clinical trials of the novel individualized immunotherapy based on the myvac® technology – First data expected in 4Q 2021
TG4001: expanded randomized Phase II trial to start in HPV-positive anogenital cancers…
Patients who received bamlanivimab and etesevimab together had an 87% reduction in hospitalizations and death; no patients died who received the therapy
VANCOUVER, British Columbia–(BUSINESS WIRE)–$ABCL #COVID19–AbCellera (Nasdaq: ABCL) today annou…
VNRX-9945 Selected as 3rd Generation Hepatitis B Virus Orally Bioavailable CpAM; Clinical Trial Application and Phase 1 Planned for Second Quarter 2021
MALVERN, Pa.–(BUSINESS WIRE)–#CpAM–Venatorx Pharmaceuticals today announced that it has selected…
Total Pharmacy® will run as an insert in the Drug Topics® publication and host content in an additional online environment
CRANBURY, N.J.–(BUSINESS WIRE)–#BusinessSolutions–Drug Topics®, a leading multimedia resource that has served the pharmacy fi…
DUBLIN–(BUSINESS WIRE)–The “Fintepla (ZX008) – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
“Fintepla (ZX008)- Emerging Insight and Market Forecast – 2030” the report provides comprehensive…